Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma.

Cancer immunology research - 3 May 2023

Romano Gabriele, Paradiso Francesca, Li Peng, Shukla Pooja, Barger Lindsay N, El Naggar Olivia, Miller John P, Liang Roger J, Helms Timothy L, Lazar Alexander J, Wargo Jennifer A, Taraballi Francesca, Costello James C, Kwong Lawrence N

Abstract excerpt

Patients with BRAF-mutant melanoma show substantial responses to combined BRAF and MEK inhibition, but most relapse within 2 years. A major reservoir for drug resistance is minimal residual disease (MRD), comprised of drug-tolerant tumor cells laying in a dormant state. Towards exploiting potential therapeutic vulnerabilities of MRD, we established a genetically engineered mouse model of BrafV600E-driven melanoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase Kinases

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 36820825
DOI: 10.1158/2326-6066.CIR-22-0224
PMCID: PMC10159986

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma.PMID 36820825Read ↗

Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanomaSemantic proximity Read ↗

Midkine Drives Reawakening of Dormant Melanoma MetastasesSemantic proximity Read ↗

Pharmacological Polarization of Tumor-Associated Macrophages Toward a CXCL9 Antitumor Phenotype.Semantic proximity Read ↗

Systemic effects of melanoma-secreted MIDKINE in the inhibition of dendritic cell differentiation and functionSemantic proximity Read ↗

BRAF/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAFV600E-mutant glioma.Semantic proximity Read ↗

Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf -Mutant MelanomaSemantic proximity Read ↗

Peptide nano-blanket impedes fibroblasts activation and subsequent formation of pre-metastatic nicheSemantic proximity Read ↗

Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor TreatmentSemantic proximity Read ↗

Harnessing the polyamine transport system to treat BRAF inhibitor-resistant melanoma.Semantic proximity Read ↗

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.Semantic proximity Read ↗

Overcoming Drug Resistance to BRAF Inhibitor.Semantic proximity Read ↗

Intratumoral administration of mRNA COVID-19 vaccine delays melanoma growth in miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.